An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination
Abstract Background Current acute myeloid leukemia (AML) therapy fails to eliminate quiescent leukemic blasts in the bone marrow, leading to about 50% of patient relapse by increasing AML burden in the bone marrow, blood, and extramedullar sites. We developed a protein-based nanoparticle conjugated...
Main Authors: | Victor Pallarès, Ugutz Unzueta, Aïda Falgàs, Laura Sánchez-García, Naroa Serna, Alberto Gallardo, Gordon A. Morris, Lorena Alba-Castellón, Patricia Álamo, Jorge Sierra, Antonio Villaverde, Esther Vázquez, Isolda Casanova, Ramon Mangues |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-04-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13045-020-00863-9 |
Similar Items
-
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells
by: Falgàs A, et al.
Published: (2021-03-01) -
Selective depletion of metastatic stem cells as therapy for human colorectal cancer
by: María Virtudes Céspedes, et al.
Published: (2018-10-01) -
Bifidobacterium bifidum does not show cell toxicity on leukemic cells of AML patients but induced cell death on K562 cell line
by: Nazanin Ghadimi, et al.
Published: (2020-09-01) -
Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4<sup>+</sup> Cancers
by: Olivia Cano-Garrido, et al.
Published: (2021-06-01) -
TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling
by: Puneet Agarwal, et al.
Published: (2021-07-01)